CompanyGraph
Kontour Xi'an Medical Technology Co. Ltd.
688314 · SSE · China
kontourmedical.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- FinancialsAltman Z-Score 10.25: safe zone
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.98%Above 5Y avg (1.25%)
Annual Rate
CNY 0.64Paid semi-annual
Payout Ratio
35.5%Sustainable
Payback Period
62.3 yr
Last Ex-Dividend
May 13, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.64BCNY393.18M · vs all stocks (USD)
Trailing P/E
30.27xvs Medical Devices peers
Revenue (TTM)
342.27MCNY50.90M · vs all stocks (USD)
Profit Margin
25.66%vs Medical Devices peers
Beta
-0.0570xvs all stocks
52-Week Change
-18.56%vs all stocks
Forward Annual Dividend Yield
1.98%vs all stocks
Market Capitalization
2.64BCNY393.18M · vs all stocks (USD)
Enterprise Value
2.39BCNY354.67M · vs all stocks (USD)
Trailing P/E
30.27xvs Medical Devices peers
Price to Sales (TTM)
7.72xvs Medical Devices peers
Price to Book (MRQ)
3.58xvs Medical Devices peers
Enterprise to Revenue
6.97xvs Medical Devices peers
Enterprise to EBITDA
19.99xvs Medical Devices peers
Gross Margin
76.72%vs Medical Devices peers
Profit Margin
25.66%vs Medical Devices peers
Operating Margin
22.68%vs Medical Devices peers
Return on Assets (TTM)
7.90%vs Medical Devices peers
Return on Equity (TTM)
12.37%vs Medical Devices peers
Revenue (TTM)
342.27MCNY50.90M · vs all stocks (USD)
Revenue per Share (TTM)
4.17CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-10.70%vs Medical Devices peers
Gross Profit (TTM)
266.67MCNY39.66M · vs all stocks (USD)
EBITDA (TTM)
114.20MCNY16.98M · vs all stocks (USD)
Net Income (TTM)
87.81MCNY13.06M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-45.30%vs Medical Devices peers
Operating Cash Flow (TTM)
117.14MCNY17.42M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
10.55MCNY1.57M · vs all stocks (USD)
Forward Annual Dividend Rate
0.6400CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
1.98%vs all stocks
Trailing Annual Dividend Rate
0.5200CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.61%vs all stocks
5-Year Average Dividend Yield
1.25%vs all stocks
Payout Ratio
35.51%vs Medical Devices peers
Minority Interest (Equity)
6.28MCNYFY2025 · Dec 31, 2025Revenue
351.08MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
74.82MCNYFY2025 · Dec 31, 2025Gross Profit
276.26MCNYFY2025 · Dec 31, 2025Operating Income
125.58MCNY18.67M · vs all stocks (USD)
Pre-tax Income
115.52MCNYFY2025 · Dec 31, 2025Income Tax Expense
17.77MCNYFY2025 · Dec 31, 2025Net Income
97.75MCNYFY2025 · Dec 31, 2025EBIT
117.84MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
139.01MCNYFY2025 · Dec 31, 2025Research & Development
25.64MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
59.26MCNYFY2025 · Dec 31, 2025Other Operating Expenses
6.25MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.03MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.32MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
97.75MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
955.22KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
74.61MCNYFY2025 · Dec 31, 2025Free Cash Flow
23.23MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
373.28MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
97.75MCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.20MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-15.56MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-11.78MCNYFY2025 · Dec 31, 2025Capital Expenditures
-51.39MCNYFY2025 · Dec 31, 2025Net Acquisitions
-46.84MCNYFY2025 · Dec 31, 2025Purchase of Investments
-15.00MCNYFY2025 · Dec 31, 2025Sale of Investments
2.21MCNYFY2025 · Dec 31, 2025Other Investing Activity
-5.35MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-116.37MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
30.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
0.00CNYFY2025 · Dec 31, 2025Common Dividends Paid
-32.78MCNYFY2025 · Dec 31, 2025Other Financing Charges
-3.19MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-5.97MCNYFY2025 · Dec 31, 2025Shares Outstanding
81.24MSharesUpdated Aug 21, 2026Float Shares
28.88MSharesUpdated Aug 21, 2026% Held by Insiders
63.91%vs all stocks
% Held by Institutions
2.53%vs all stocks
Total Cash (MRQ)
359.45MCNY53.45M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.42CNYUpdated Aug 21, 2026Total Debt (MRQ)
86.19MCNY12.82M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1163xvs Medical Devices peers
Current Ratio (MRQ)
4.31xvs Medical Devices peers
Book Value per Share (MRQ)
9.05CNYUpdated Aug 21, 2026Total Assets
909.16MCNY135.20M · vs all stocks (USD)
Total Current Assets
443.39MCNYFY2025 · Dec 31, 2025Total Liabilities
185.12MCNYFY2025 · Dec 31, 2025Total Non-current Assets
465.77MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
80.05MCNYFY2025 · Dec 31, 2025Total Current Liabilities
105.07MCNYFY2025 · Dec 31, 2025Cash
373.28MCNYFY2025 · Dec 31, 2025Cash Equivalents
790.06KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
374.07MCNYFY2025 · Dec 31, 2025Accounts Receivable
17.94MCNYFY2025 · Dec 31, 2025Inventory
32.62MCNYFY2025 · Dec 31, 2025Accounts Payable
23.08MCNYFY2025 · Dec 31, 2025Short-term Debt
47.17MCNYFY2025 · Dec 31, 2025Other Current Liabilities
409.53KCNYFY2025 · Dec 31, 2025Long-term Debt
40.58MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
77.23KCNYFY2025 · Dec 31, 2025Common Stock (Book)
81.24MCNYFY2025 · Dec 31, 2025Retained Earnings
272.64MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
724.04MCNY107.67M · vs all stocks (USD)
Treasury Stock
0.00CNYFY2025 · Dec 31, 202552-Week Low
28.00CNYUpdated Aug 21, 202652-Week High
58.60CNYUpdated Aug 21, 202652-Week Change
-18.56%vs all stocks
Beta
-0.0570xvs all stocks
50-Day MA
34.25CNYUpdated Aug 21, 2026200-Day MA
38.49CNYUpdated Aug 21, 2026Avg 10-Day Volume
834.41KSharesUpdated Aug 21, 2026Avg 30-Day Volume
1.27MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.07CNYUpdated Aug 21, 20268 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 10.25: safe zoneNotable
Altman Z-Score: 10.25
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Foresee Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
United States Lime & Minerals Inc.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthCash Elevated Relative to Current Liabilities and Total AssetsRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
Classys Inc.
7 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
Pharma Research Products Co., Ltd
7 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin